Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology

Background & Aims: Non-alcoholic fatty liver disease (NAFLD) has become a major public health problem, but the prevalence of fibrosis associated with non-alcoholic steatohepatitis (NASH) is largely unknown in the general population. This study aimed to provide an updated estimation of the preval...

Descripción completa

Detalles Bibliográficos
Autores: Calleja, Jose Luis|||0000-0002-2265-6591, Rivera Esteban, Jesús|||0000-0003-4357-8817, Aller, Rocio, Hernández-Conde, Marta|||0000-0002-7153-0493, Abad, Javier, Pericàs, Juan M.|||0000-0002-3645-3293, Benito, Hugo G., Serra, Miguel A., Escudero, Amparo, Ampuero, Javier|||0000-0002-8332-2122, Lucena, Ana, Sánchez, Yolanda, Arias-Loste, Maria T.|||0000-0001-8864-3833, Iruzubieta, Paula|||0000-0001-9476-1801, Romero-Gómez, Manuel|||0000-0001-8494-8947, Augustin Recio, Salvador|||0000-0002-3515-9033, Crespo García, Javier|||0000-0001-8248-0172
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:259776
Acceso en línea:https://ddd.uab.cat/record/259776
https://dx.doi.org/urn:doi:10.1111/liv.15323
Access Level:acceso abierto
Palabra clave:Hepatic fibrosis
Liver biopsy
Non-alcoholic steatohepatitis
Transient elastography
Descripción
Sumario:Background & Aims: Non-alcoholic fatty liver disease (NAFLD) has become a major public health problem, but the prevalence of fibrosis associated with non-alcoholic steatohepatitis (NASH) is largely unknown in the general population. This study aimed to provide an updated estimation of the prevalence of NASH fibrosis in Spain. Methods: This was an observational, retrospective, cross-sectional, population-based study with merged data from two Spanish datasets: a large (N = 12 246) population-based cohort (ETHON), including transient elastography (TE) data, and a contemporary multi-centric biopsy-proven NASH cohort with paired TE data from tertiary centres (N = 501). Prevalence for each NASH fibrosis stage was estimated by crossing TE data from ETHON dataset with histology data from the biopsy-proven cohort. Results: From the patients with valid TE in ETHON dataset (N = 11 440), 5.61% (95% confidence interval [95% CI]: 2.53-11.97) had a liver stiffness measurement (LSM) ≥ 8 kPa. The proportion attributable to NAFLD (using clinical variables and Controlled Attenuation Parameter) was 57.3% and thus, the estimated prevalence of population with LSM ≥ 8 kPa because of NAFLD was 3.21% (95% CI 1.13-8.75). In the biopsy-proven NASH cohort, 389 patients had LSM ≥ 8 kPa. Among these, 37% did not have significant fibrosis (F2-4). The estimated prevalence of NASH F2-3 and cirrhosis in Spain's adult population were 1.33% (95% CI 0.29-5.98) and 0.70% (95% CI 0.10-4.95) respectively. Conclusions: These estimations provide an accurate picture of the current prevalence of NASH-related fibrosis in Spain and can serve as reference point for dimensioning the therapeutic efforts that will be required as NASH therapies become available.

Similares en LA Referencia